Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Sponsor

McMaster University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05740748

Collaborator

University of Saskatchewan (Other)

Enrollment

Locations

Arms

Anticipated Duration (Months)

Patients Per Site

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.

Condition or Disease	Intervention/Treatment	Phase
Asthma, Allergic	Drug: Tezepelumab Drug: Placebo	Phase 2

Detailed Description

The proposed study will address whether tezepelumab has the unique ability to improve AHR in participants with mild allergic asthma.

This is a phase 2 multi-centre randomized double-blind placebo-controlled parallel-group study to examine the effects of 24 weeks tezepelumab 210 mg sc q4wks on methacholine airway hyperresponsiveness in participants with mild allergic asthma, stratified for sex and sensitivity to seasonal allergens.

There are 9 study visits over a period of 27 weeks (Figure 1). Study procedures performed at Weeks -1, 8, 16 and 24 will be divided across 2 visits at least 48 hours apart for measurement of AHR to methacholine first, and mannitol at least 48 hours later.

The screening period at Week -1 will determine eligibility. At Week -1, eligible allergic mild asthmatic participants will be randomized 1:1 to placebo or tezepelumab 210 mg subcutaneous administered monthly for a total of 24 weeks. AHR will be measured by methacholine and mannitol challenges at baseline (Week -1) performed at least 48 hours apart. Changes in AHR response will be measured by repeat methacholine and mannitol challenges at Weeks 8, 16 and 24.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

34 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Phase 2 Multi-centre Randomized Double-blind Placebo-controlled Parallel Group Study to Examine the Effects of 24 Weeks Tezepelumab 210 mg sc q4wks on Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Anticipated Study Start Date :

Apr 1, 2023

Anticipated Primary Completion Date :

Dec 30, 2024

Anticipated Study Completion Date :

Dec 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Tezepelumab tezepelumab 210 mg sc q4wks 20 weeks treatment	Drug: Tezepelumab tezepelumab 210 mg sc q4wks for 20 weeks
Placebo Comparator: Placebo placebo sc q4wks 20 weeks treatment	Drug: Placebo placebo sc q4wks for 20 weeks

Arm

Intervention/Treatment

Experimental: Tezepelumab

tezepelumab 210 mg sc q4wks 20 weeks treatment

Drug: Tezepelumab

tezepelumab 210 mg sc q4wks for 20 weeks

Placebo Comparator: Placebo

placebo sc q4wks 20 weeks treatment

Drug: Placebo

placebo sc q4wks for 20 weeks

Outcome Measures

Primary Outcome Measures

Methacholine PD20 [Week -1 to Week 24]
The provocative dose of methacholine causing 20% fall in FEV1

Secondary Outcome Measures

Dose response ratio to mannitol [Week -1 to Week 24]
The mannitol dose response ratio calculated by dividing the total cumulative dose by the % fall in FEV1 at that dose.
Mast cell tryptase levels. [Week -1 to Week 24]
Level of mast cell-derived tryptase in blood and urine at Week 24.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of informed consent prior to any study specific procedures
Male and female 18 through 65 years of age
Positive skin-prick test to a common aeroallergen
Methacholine PD20 ≤ 200mcg
Mannitol DRR ≤ 42.3mg/FEV1 %f all (equivalent to PD15 ≤ 635mg)
Baseline FEV1 ≥ 70% of the predicted value
Negative pregnancy test (urine) for female participants of childbearing potential.

Exclusion Criteria:

Current or former smoker with >10-pack-year history
Current or previous history of lung disease other than mild stable allergic asthma
Significant systemic disease, including history of current malignancy or autoimmune disease
Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)
Previous randomisation in the present study. Re-screening (Week -1) for FEV1 and AHR is permitted once for each test.
Participation in another clinical study with an investigational product during the last 30 days or 5 half-lives of the drug (whichever is longer)
Use of any medications for treatment of asthma other than prophylactic short-acting β2-agonists, or use of short-acting β2-agonists for relief of symptoms less than once weekly.
Participants with known hypersensitivity to tezepelumab or any of the excipients of the product.
Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening
Known to have tested positive for human immunodeficiency virus
Known history of drug or alcohol abuse within 1 year of screening
For women only - currently pregnant (confirmed with positive pregnancy test) or breast feeding.
Unwillingness or inability to comply with the study protocol for any other reason.